Abstract:ID 130936 Poster Board 493 The receptor for pituitary adenylate cyclase-activating polypeptide (PACAP) is a Gs-coupled GPCR, designated PAC1. Antagonists of this receptor are being pursued for their potential to ameliorate atherosclerogenesis, depression, post-traumatic stress disorder, and migraine; discovery of agonists is also of interest for counteracting the neurodegenerative consequences of stroke and ischemia. However, obtaining small-molecule ligands (SMOLs) for this receptor has been challenging. Peptide-based antagonists include an N-terminally truncated version of PACAP38 (P38) itself, PACAP6-38 (P6-38). The activity of P6-38 as an antagonist is consistent with models of PACAP binding to PAC1 in which the N-terminus of PACAP is required for receptor activation leading to signaling through the Gs protein, while the C-terminus is involved in initial binding (affinity-trapping) to PAC1. P6-38 has been shown repeatedly to block the action of P38 as well as the naturally occurring ligand PACAP1-27 (P27) both in vivo and in cells expressing endogenous PAC1. Several SMOLs reported to be PAC1 antagonists in the literature were tested for antagonist activity in HEK293 cells expressing the human PAC1 receptor and a cAMP biosensor (CBS)-based cAMP detection system; however not only these but also P6 -38 were without inhibitory effect in this assay system. Accordingly, we re-tested the inhibitory activity of P6-38 against both P27 and P38 in cells expressing CBS but with native expression of PAC1: the rat NS-1 pheochromocytoma cell line, and the human SH-SY5Y neuroblastoma cell line. Both CBS-based luminescent read-out, and generation of cAMP provoked by exposure to EC50 concentrations of P27 or P38 (0.2 nM) were blocked by 1 mM P6-38 which also blocked downstream signaling effects (neuritogenesis) of P27 and P38. Recently, cryo-EM structures of a number of family B (secretin family) GPCR-ligand structures have been obtained, allowing detailed molecular dynamics analysis of ligand-receptor binding, and prediction of residues contributing most strongly to ligand engagement. Molecular dynamics simulations predicted initial receptor engagement with residues 6-30, but not 31-38, of P38. Accordingly, we synthesized a series of deletants of PACAP6-38 and tested their relative inhibitory potency in SH-SY5Y and NS-1 cells. PACAP6-30 (IC50 ~33 nM) was nearly as potent as PACAP6-38 (IC50 ~21 nM) as an inhibitor of cyclic AMP elevation by 0.2 nM P38 (the approximate EC50 for both the CBS-based and the direct cAMP assay, both carried out in the presence of phosphodiesterase inhibition by IBMX). PACAP6-27 was considerably less potent (IC 50 >10 mM). Thus, the affinity-trap model for PAC1-ligand interaction successfully predicts the behavior of peptide-based inhibitors of P27 and P38 engagement with an endogenously expressed PAC1 receptor. We are currently engaged in peptide modification of P6-30 in order to increase the potency of this PAC1 antagonist.

IP3RPEP6, a novel peptide inhibitor of IP3 receptor channels that does not affect connexin‐43 hemichannels

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Functional investigation of a putative calcium-binding site involved in the inhibition of inositol 1,4,5-trisphosphate receptor activity

Structural basis for the regulation of inositol trisphosphate receptors by Ca2+ and IP3

IP3 receptor isoforms differently regulate ER-mitochondrial contacts and local calcium transfer

Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca2+ signaling output

Membrane permeable cyclic peptidyl inhibitors against human Peptidylprolyl Isomerase Pin1.

Understanding IP3R channels: From structural underpinnings to ligand-dependent conformational landscape

Functional Determination of Calcium Binding Sites Required for the Activation of Inositol 1,4,5-trisphosphate receptors

Agonist-Induced Ca2+ Signaling in HEK-293-Derived Cells Expressing a Single IP3 Receptor Isoform

d-chiro-Inositol Ribophostin: A Highly Potent Agonist of d-myo-Inositol 1,4,5-Trisphosphate Receptors: Synthesis and Biological Activities

Endogenously bound calmodulin is essential for the function of the inositol 1,4,5-trisphosphate receptor

Ligand-Induced Conformational Changes in Tetrameric Ip(3)R1 Revealed by Single-Particle Cryo-Em

An Expanded Biological Repertoire for Ins(3,4,5,6)P4 Through Its Modulation of ClC-3 Function

Structural and functional insight into a new emerging target IP3R in cancer

PI(3,4,5)P3 potentiates phospholipase C-beta activity

A nonnatural peptide targeting the A-kinase anchoring function of PI3Kγ for therapeutic cAMP modulation in pulmonary cells

PACAP Deletants as Peptide-based PACAP Antagonists

Opto-chemogenetic inhibition of L-type CaV1 channels in neurons through a membrane-assisted molecular linkage

Pre-clinical proof-of-concept of anti-fibrotic activity of caveolin-1 scaffolding domain peptide LTI-03 in precision cut lung slices from patients with Idiopathic Pulmonary Fibrosis

Inhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3